U.S. markets closed

Perrigo Company plc (0Y5E.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
75.69+21.80 (+40.45%)
At close: 11:52AM BST
Full screen
Loading interactive chart...
  • Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss

    Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss

    Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.

  • Perrigo (PRGO) Q2 Earnings Beat Estimates

    Perrigo (PRGO) Q2 Earnings Beat Estimates

    Perrigo (PRGO) delivered earnings and revenue surprises of 18.39% and -0.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Perrigo Q2 Earnings

    Shares of Perrigo (NYSE:PRGO) rose 0.9% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 19.77% over the past year to $1.03, which beat the estimate of $0.88.Revenue of $1,219,000,000 rose by 8.16% from the same period last year, which missed the estimate of $1,240,000,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Aug 05, 2020View more earnings on PRGOTime: 09:00 AMET Webcast URL: https://investor.perrigo.com/events-webcastsTechnicals Company's 52-week high was at $63.8652-week low: $40.01Price action over last quarter: Up 5.58%Company Description Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to over the counter and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.See more from Benzinga * Earnings Scheduled For August 5, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.